Kiniksa Pharmaceuticals International (KNSA) investor relations material

Business overview and commercial performance

• Achieved strong Q1 growth, raising 2026 net revenue guidance for ARCALYST in recurrent pericarditis to $930–$945 million.

• Five years post-launch, ARCALYST saw record quarter-on-quarter growth in new prescribers and patient enrollments.

• Penetration into the 2+ recurrence patient group reached 18%, with opportunity for further expansion.

• About 50% of prescriptions now come from repeat prescribers, reflecting growing physician adoption.

• Patient awareness remains low at 14%, but conversion to prescription is high when awareness is achieved.

Market dynamics and physician engagement

• Target addressable population is 40,000 annually, with 14,000 experiencing multiple recurrences.

• Shift observed toward earlier use of ARCALYST, with 20% of prescriptions now for first recurrence.

• Outreach includes field force, medical affairs, and partnerships with 18 specialist centers.

• Direct-to-consumer campaigns leverage AI and machine learning for targeted patient education.

• Ongoing efforts to change treatment paradigms and increase prescriber base among 25,000 physicians.

Pipeline and clinical development

• KPL-387 phase II/III trial underway; phase II data expected in H2 2026, with phase III initiation planned by year-end.

• KPL-387 aims for once-monthly self-injection, with dose selection based on PK/PD and durability data.

• KPL-1161, an Fc-modified monoclonal antibody, set to enter phase I trials by end of year.

• Clinical strategy focuses on matching treatment duration to disease duration, using risk scores and patient monitoring.

• Future positioning of ARCALYST and KPL-387 to be determined as pipeline matures.